Oral faecal microbiota transplantation in ulcerative colitis

Affiliations

¹ Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.
² Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore. Electronic address: malcolm.tan.t.k@singhealth.com.sg.

Comment

Tan Yi Yuan et al. Lancet Gastroenterol Hepatol. 2022 Apr.

. 2022 Apr;7(4):286.

doi: 10.1016/S2468-1253(21)00469-6.

¹ Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore.
² Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore 169608, Singapore. Electronic address: malcolm.tan.t.k@singhealth.com.sg.

No abstract available

Conflict of interest statement

MT reports personal fees from Ferring, Johnson & Johnson, Pfizer, and Takeda. TYY and RR declare no competing interests.

Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
Haifer C, Paramsothy S, Kaakoush NO, Leong RW. Haifer C, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):286-287. doi: 10.1016/S2468-1253(22)00045-0. Lancet Gastroenterol Hepatol. 2022. PMID: 35278396 No abstract available.

Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, Luu LDW, Borody TJ, Leong RW. Haifer C, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3. Epub 2021 Dec 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34863330 Clinical Trial.